1
|
Pirlamarla AK, Hansen CC, Deng M, Handorf E, Paly J, Wong JK, Hallman MA, Chen DYT, Geynisman DM, Kutikov A, Horwitz EM. Early PSA kinetics for low- and intermediate-risk prostate cancer treated with definitive radiation therapy. Pract Radiat Oncol 2021; 12:60-67. [PMID: 34303033 DOI: 10.1016/j.prro.2021.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Revised: 07/08/2021] [Accepted: 07/12/2021] [Indexed: 12/24/2022]
Abstract
PURPOSE This study uses a patient-specific model to characterize and compare ideal PSA kinetics for low- and intermediate-risk prostate cancer following definitive radiation treatment with conventionally fractionated (CFRT), hypofractionated (HFRT), stereotactic body radiation therapy (SbRT), or brachytherapy, both high-dose-rate (HDR) and low-dose-rate (LDR). METHODS AND MATERIALS This retrospective analysis includes low- and intermediate-risk prostate cancer patients treated between 1998 and 2018 at an NCI-designated Comprehensive Cancer Center. Demographics and treatment characteristics were prospectively collected. Patients had at least two PSA measurements within 24-months of treatment and were free from biochemical recurrence. The incidence of, time to, and risk factors for PSA nadir (nPSA) and bounce (bPSA) were analyzed at 24-months following radiotherapy. Ideal PSA kinetics were characterized for each modality and compared. RESULTS Of 1,042 patients, 45% had low-risk cancer, 37% favorable intermediate-risk, and 19% unfavorable intermediate-risk. nPSA were higher for ablative modalities, both as absolute nPSA and relative to initial PSA (iPSA). Median time to nPSA ranged from 14.8 to 17.1 months. Over 50% treated with non-ablative therapy (CFRT, HFRT, and LDR) reached an nPSA threshold of ≤0.5 ng/mL compared to 23% of SbRT and 33% of HDR cohorts. The incidence of bPSA was 13.3% and not affected by treatment modality, Gleason Score, or prostate volume. PSA decay rate was faster for ablative therapies in the 6-24 month period. CONCLUSIONS Analysis of PSA within 24-months following radiation therapy revealed ablative therapies are associated with a latent PSA response and higher nPSA. Multivariable logistics modeling revealed younger age, iPSA above the median, presence of bPSA, and ablative therapy as predictors for not achieving nPSA ≤0.5 ng/mL. PSA decay rate appears to be faster in ablative therapies following a latent period. Understanding the different PSA kinetic profiles is necessary to assess treatment response and survey for disease recurrence.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - David Y T Chen
- Departments of Urologic Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111
| | - Daniel M Geynisman
- Departments of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111
| | - Alexander Kutikov
- Departments of Urologic Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111
| | | |
Collapse
|
2
|
Bellera C, Proust-Lima C, Joseph L, Richaud P, Taylor J, Sandler H, Hanley J, Mathoulin-Pélissier S. A two-stage model in a Bayesian framework to estimate a survival endpoint in the presence of confounding by indication. Stat Methods Med Res 2016; 27:1271-1281. [DOI: 10.1177/0962280216660127] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background Biomarker series can indicate disease progression and predict clinical endpoints. When a treatment is prescribed depending on the biomarker, confounding by indication might be introduced if the treatment modifies the marker profile and risk of failure. Objective Our aim was to highlight the flexibility of a two-stage model fitted within a Bayesian Markov Chain Monte Carlo framework. For this purpose, we monitored the prostate-specific antigens in prostate cancer patients treated with external beam radiation therapy. In the presence of rising prostate-specific antigens after external beam radiation therapy, salvage hormone therapy can be prescribed to reduce both the prostate-specific antigens concentration and the risk of clinical failure, an illustration of confounding by indication. We focused on the assessment of the prognostic value of hormone therapy and prostate-specific antigens trajectory on the risk of failure. Methods We used a two-stage model within a Bayesian framework to assess the role of the prostate-specific antigens profile on clinical failure while accounting for a secondary treatment prescribed by indication. We modeled prostate-specific antigens using a hierarchical piecewise linear trajectory with a random changepoint. Residual prostate-specific antigens variability was expressed as a function of prostate-specific antigens concentration. Covariates in the survival model included hormone therapy, baseline characteristics, and individual predictions of the prostate-specific antigens nadir and timing and prostate-specific antigens slopes before and after the nadir as provided by the longitudinal process. Results We showed positive associations between an increased prostate-specific antigens nadir, an earlier changepoint and a steeper post-nadir slope with an increased risk of failure. Importantly, we highlighted a significant benefit of hormone therapy, an effect that was not observed when the prostate-specific antigens trajectory was not accounted for in the survival model. Conclusion Our modeling strategy was particularly flexible and accounted for multiple complex features of longitudinal and survival data, including the presence of a random changepoint and a time-dependent covariate.
Collapse
Affiliation(s)
- Carine Bellera
- Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
- INSERM CIC-EC 14.01 (Clinical Epidemiology), Bordeaux, France
- INSERM, ISPED, Centre INSERM U1219 Bordeaux Population Health Center, Epicene Team, F-33000 Bordeaux, France
- Univ. Bordeaux, ISPED, Centre INSERM U1219 Bordeaux Population Health, Epicene Team, F-33000 Bordeaux, France
| | - Cécile Proust-Lima
- INSERM CIC-EC 14.01 (Clinical Epidemiology), Bordeaux, France
- INSERM, ISPED, Centre INSERM U1219 Bordeaux Population Health Center, Biostatistics Team, F-33000 Bordeaux, France
- Univ. Bordeaux, ISPED, Centre INSERM U1219 Bordeaux Population Health, Biostatistics Team, F-33000 Bordeaux, France
| | - Lawrence Joseph
- Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
| | - Pierre Richaud
- Department of Radiotherapy, Comprehensive Cancer Center, Institut Bergonié, France
| | - Jeremy Taylor
- Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
| | - Howard Sandler
- Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, USA
| | - James Hanley
- Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
| | - Simone Mathoulin-Pélissier
- Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
- INSERM CIC-EC 14.01 (Clinical Epidemiology), Bordeaux, France
- INSERM, ISPED, Centre INSERM U1219 Bordeaux Population Health Center, Epicene Team, F-33000 Bordeaux, France
- Univ. Bordeaux, ISPED, Centre INSERM U1219 Bordeaux Population Health, Epicene Team, F-33000 Bordeaux, France
| |
Collapse
|
3
|
Bellera CA, Hanley JA, Joseph L, Albertsen PC. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer. Ann Epidemiol 2008; 18:270-82. [PMID: 18374279 DOI: 10.1016/j.annepidem.2007.10.006] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2007] [Revised: 09/25/2007] [Accepted: 10/05/2007] [Indexed: 11/26/2022]
Abstract
PURPOSE Biomarkers provide valuable information when detecting disease onset or monitoring disease progression; examples include bone mineral density (for osteoporosis), cholesterol (for coronary artery diseases), or prostate-specific antigens (PSA, for prostate cancer). Characteristics of markers series can then be used as prognostic factors of disease progression, such as the postradiotherapy PSA doubling time in men treated for prostate cancer. The statistical analysis of such data has to incorporate the within and between-series variabilities, the complex patterns of the series over time, the unbalanced format of the data, and the possibly nonconstant precision of the measurements. METHODS We base our analysis on a population-based cohort of 470 men treated with radiotherapy for prostate cancer; after treatment, the log(2)PSA concentrations follow a piecewise-linear pattern. We illustrate the flexibility of Bayesian hierarchical changepoint models by estimating the individual and population postradiotherapy log(2)PSA profiles; parameters such as the PSA nadir and the PSA doubling time were estimated, and their associations with baseline patient characteristics were investigated. The residual PSA variability was modeled as a function of the PSA concentration. For comparison purposes, two alternative models were briefly considered. RESULTS Precise estimates of all parameters of the PSA trajectory are provided at both the individual and population levels. Estimates suggest greater PSA variability at lower PSA concentrations, as well as an association between shorter PSAdts and greater baseline PSA levels, higher Gleason scores, and older age. CONCLUSIONS The use of Bayesian hierarchical changepoint models accommodates multiple complex features of longitudinal data, permits realistic modeling of the variability as a function of the marker concentration, and provides precise estimates of all clinically important parameters. This type of model should be applicable to the study of marker series in other diseases.
Collapse
Affiliation(s)
- Carine A Bellera
- Department of Clinical Epidemiology and Clinical Research, Institut Bergonié, Regional Comprehensive Cancer Center, Bordeaux, France.
| | | | | | | |
Collapse
|
4
|
|
5
|
Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol 2003; 43:12-27. [PMID: 12507539 DOI: 10.1016/s0302-2838(02)00505-5] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Prostate-specific antigen (PSA) progression following radical treatments of clinically localized prostate cancer is a common problem facing both the patient and the urologist. Not all patients with relapsing disease have an equal risk of death due to prostate cancer. After surgery, biochemical failure can be defined as persisting detectable levels of PSA after radical prostatectomy or a PSA rise after a period of normalization. On the other hand, definitions of PSA progression after radiation therapy vary and no clear consensus can be found. This review of the recent international literature updates the knowledge about the diagnostic procedures used in relapsing patients. Predictors of progression are precised leading to a better patient selection, based on currently available tables and nomograms. Indeed, identification of high risk patients may allow a more appropriate treatment decision. After radical treatment, the analysis of time to recurrence, PSA doubling time, PSA kinetics combined to modern imaging techniques such as 111In capromab penditide scan may allow a better identification of the recurrence site. Thus, an optimal treatment strategy may be envisaged such as local irradiation, salvage surgery, hormone therapy or combinations for which indications and results are provided. Alternative options such as cryotherapy still need further investigation. At last, the use of artificial neural networks will certainly enhance the selection of patients submitted to radical treatments as well as the selection of relapsing patients to allow a more appropriate adjuvant therapy.
Collapse
Affiliation(s)
- Bob Djavan
- Department of Urology, University of Vienna, Waehringer Guertel 18-20, Vienna A-1090, Austria.
| | | | | | | | | |
Collapse
|
6
|
Salem N. [Clinical and biological surveillance after radiotherapy for localized prostate cancer]. Cancer Radiother 2002; 6:159-67. [PMID: 12116841 DOI: 10.1016/s1278-3218(02)00151-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Serum PSA is an excellent marker of disease status after external beam radiotherapy or brachytherapy for patients with prostate carcinoma. A low PSA nadir < or = 1 even < or = 0.5 ng/mL has been shown to be as a surrogate end point for disease control. Three successive increases of this marker after achieving the nadir defines recurrence as recommended by the American Society for Therapeutic Radiology and Oncology. The biochemical relapse or PSA failure after treatment precedes clinical disease relapse by several months. PSA profile or kinetics may have implications for patterns of failure and prognosis. Prostate post-radiotherapy biopsies should not be part of routine follow-up as its interpretation is frequently problematic. Other exams should not be performed unless clinical symptoms are present. Post-radiotherapy relapse treatment has generally no curative intent.
Collapse
Affiliation(s)
- N Salem
- Département de radiothérapie, institut Paoli-Calmettes, 232, Boulevard-Sainte-Marguerite, 13273 Marseille, France.
| |
Collapse
|
7
|
Perez CA, Michalski JM, Lockett MA. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint. Int J Radiat Oncol Biol Phys 2001; 49:1287-96. [PMID: 11286836 DOI: 10.1016/s0360-3016(00)01492-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE To compare postirradiation biochemical disease-free survival using the American Society of Therapeutic Radiology and Oncology (ASTRO) Consensus or elevation of postirradiation prostate-specific antigen (PSA) level beyond 1 ng/mL as an endpoint and correlate chemical failure with subsequent appearance of clinically detected local recurrence or distant metastasis. METHODS AND MATERIALS Records of 466 patients with histologically confirmed adenocarcinoma of the prostate treated with irradiation alone between January 1987 and December 1995 were analyzed; 339 patients were treated with bilateral 120 degrees arc rotation and, starting in 1992, 117 with three-dimensional conformal irradiation. Doses were 68--77 Gy in 1.8 to 2 Gy daily fractions. Minimum follow-up is 4 years (mean, 5.5 years; maximum, 9.6 years). A chemical failure was recorded using the ASTRO Consensus or when postirradiation PSA level exceeded 1 ng/mL at any time. Clinical failures were determined by rectal examination, radiographic studies, and, when clinically indicated, biopsy. RESULTS Six-year chemical disease-free survival rates using the ASTRO Consensus according to pretreatment PSA level for T1 tumors were: < or = 4 ng/mL, 100%; 4.1--20 ng/mL, 80%; and > 20 ng/mL, 50%. For T2 tumors the rates were: < or = 4 ng/mL, 91%; 4.1--10 ng/mL, 81%; 10.1--20 ng/mL, 55%; 20.1--40 ng/mL, 63%; and > 40 ng/mL, 46%. When postirradiation PSA levels higher than 1 ng/mL were used, the corresponding 6-year chemical disease-free survival rates for T1 tumors were 92% for pretreatment PSA levels of < or = 4 ng/mL, 58--60% for levels of 4.1--20 ng/mL, and 30% for levels > 20 ng/mL. For T2 tumors, the 6-year chemical disease-free survival rates were 78% in patients with pretreatment PSA levels of 4--10 ng/mL, 45% for 10.1--40 ng/mL, and 25% for > 40 ng/mL. Of 167 patients with T1 tumors, 30 (18%) developed a chemical failure, 97% within 5 years from completion of radiation therapy; no patient has developed a local recurrence or distant metastasis. In patients with T2 tumors, overall 45 of 236 (19%) had chemical failure, 94% within 5 years of completion of radiation therapy; 4% have developed a local recurrence, and 10%, distant metastasis. In patients with T3 tumors, overall, 24 of 65 (37%) developed a chemical failure, 100% within 3.5 years from completion of radiation therapy; 4% of these patients developed a local recurrence within 2 years, and 12% developed distant metastasis within 4 years of completion of irradiation. The average time to clinical appearance of local recurrence or distant metastasis after a chemical failure was detected was 5 years and 3 years, respectively. CONCLUSION There was a close correlation between the postirradiation nadir PSA and subsequent development of a chemical failure. Except for patients with T1 tumors and pretreatment PSA of 4.1--20 ng/mL, there is good agreement in 6-year chemical disease-free survival using the ASTRO Consensus or PSA elevations above 1 ng/mL as an endpoint. Although the ASTRO Consensus tends to give a higher percentage of chemical disease-free survival in most groups, the differences with longer follow-up are not statistically significant (p > 0.05). It is important to follow these patients for at least 10 years to better assess the significance of and the relationship between chemical and clinical failures.
Collapse
Affiliation(s)
- C A Perez
- Radiation Oncology Center, Mallinckrodt Institute of Radiology, Washington University Medical Center, St. Louis, MO 63108, USA.
| | | | | |
Collapse
|
8
|
Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000; 46:839-50. [PMID: 10705004 DOI: 10.1016/s0360-3016(99)00499-x] [Citation(s) in RCA: 237] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
PURPOSE A report of biochemical outcomes for patients treated with palladium-103 (Pd-103) brachytherapy over a fixed time interval. METHODS AND MATERIALS Two hundred thirty patients with clinical stage T1-T2 prostate cancer were treated with Pd-103 brachytherapy and followed with prostate-specific antigen (PSA) determinations. Kaplan-Meier estimates of biochemical failure on the basis of two consecutive elevations of PSA were utilized. Multivariate risk groups were constructed. Aggregate PSA response by time interval was assessed. RESULTS The overall biochemical control rate achieved at 9 years was 83.5%. Failures were local 3.0%; distant 6.1%; PSA progression only 4.3%. Significant risk factors contributing to failure were serum PSA greater than 10 ng/ml and Gleason sum of 7 or greater. Five-year biochemical control for those exhibiting neither risk factor was 94%; one risk factor, 82%; both risk factors, 65%. When all 1354 PSA determinations obtained for this cohort were considered, the patients with a proportion of PSAs < or = 0.5 ng/ml continued to increase until at least 48 months post-therapy. These data conformed to a median PSA half-life of 96.2 days. CONCLUSIONS Prostate brachytherapy with Pd-103 achieves a high rate of biochemical and clinical control in patients with clinically organ-confined disease. PSA response following brachytherapy with low-dose-rate isotopes is protracted.
Collapse
Affiliation(s)
- J C Blasko
- Seattle Prostate Institute, Seattle, WA 98104, USA.
| | | | | | | | | | | |
Collapse
|
9
|
Jani AB, Chen MH, Vaida F, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S. PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention. Urology 1999; 54:700-5. [PMID: 10510931 DOI: 10.1016/s0090-4295(99)00229-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES To examine pretreatment variables that influence biochemical failure, and to describe and test a new definition of prostate-specific antigen (PSA)-based biochemical failure. METHODS We introduce and describe a new definition of biochemical failure, which is based on quadratic fitting of the logarithm of the follow-up PSA profile curve. From a data base of 449 patients with prostate cancer treated with definitive radiation therapy, 230 patients who had at least five follow-up PSA observations were chosen for analysis. The new definition of failure was applied to this cohort, as was the conventional definition of two consecutive PSA rises. Univariate and multivariate analyses were performed using established pretreatment prognostic factors as covariates. Also, the association of both definitions of failure with clinical outcome (local recurrence and any recurrence) was examined. RESULTS Application of the new definition of biochemical failure resulted in smoothing of the "noise" that is inherent in using definitions based on successive PSA rises. This smoothing was verified by smaller P values for the statistically significant covariates in the univariate analysis. Furthermore, the new definition correlated better with clinical outcome, as demonstrated by the statistically significant P values on regression analysis when using the quadratic fitted nadir compared with using the observed nadir. CONCLUSIONS We devised a new criterion based on quadratic curve fitting for PSA-based biochemical failure. This definition is based on all available PSA information, correlates with both pretreatment factors and post-treatment clinical outcome, is relatively insensitive to noise, and allows for prediction of time of failure.
Collapse
Affiliation(s)
- A B Jani
- Department of Radiation and Cellular Oncology, University of Chicago, Illinois, USA
| | | | | | | | | | | | | |
Collapse
|
10
|
|
11
|
Ennis RD, Malyszko BK, Heitjan DF, Rubin MA, O'Toole KM, Schiff PB. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41:511-7. [PMID: 9635696 DOI: 10.1016/s0360-3016(98)00104-7] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE The optimal definition of biochemical recurrence of prostate cancer after definitive radiotherapy remains elusive. Different institutions have developed their own definitions, and a consensus conference (CC) sponsored by the American Society for Therapeutic Radiology and Oncology has recently proposed another definition. This study compares the definition previously used at our institution with the definition proposed by the CC. METHODS Two hundred and eight patients were treated for localized prostate cancer with conformal external-beam radiotherapy between 1989-1993 at our institution and followed for at least 24 months. Patients were categorized as failures according to our institutional definition and the CC definition. Our definition (CPMC) required two increases in serum prostate specific antigen (PSA) over at least a 3-month period with a final value of at least 1 ng/ml or a single value resulting in clinical intervention. The CC definition required three consecutive increases in PSA. This was modified to also consider those patients with one or two increases leading to clinical intervention as failures. Differences in the failure rates between the two definitions were evaluated and factors influencing these differences were explored. In an additional analysis, CC was modified such that patients with one or two PSA increases were censored at the time of the PSA prior to the increases (CC-II), rather than at the last PSA (CC). The median follow-up time was 31 months. RESULTS There were 36 fewer failures according to CC (n = 96) compared with CPMC (n = 132) (p < 0.001). Twenty cases called failures by CPMC subsequently had a decrease in PSA ("false failures"). The other 16 patients have had two increases in PSA, but are awaiting their next follow-up visit to obtain a third PSA ("pending failures"). Analysis of factors predicting "pending failures" showed Gleason score to be the sole predictor of this change in status in multivariate analysis (p = 0.03) with patients with lower-grade tumors being more likely to change status (Gleason 2-6: 15% vs. Gleason 7-10: 1%). On the other hand, "false failures," compared to true failures, had a lower mean PSA nadir (1.7 ng/ml vs. 7.0 ng/ml, p < 0.001) and significantly smaller mean increases in PSA (1st increase: 0.6 ng/ml vs. 3.4 ng/ml, p = 0.006; 2nd increase: 0.4 ng/ml vs. 4.8 ng/ml, p = 0.002). In 85% (17 of 20) of these patients, at least one of the increases was < or = 0.3 ng/ml compared with 44% (42 of 96) of the true failures (p = 0.0008). CC-II resulted in a small decrease in BDFS rates compared with CC, but did not affect the overall difference between CC and CPMC. A modified definition that defines failure as two consecutive increases in PSA over 3 months, with a final value greater than 1.0 ng/ml and each increase being at least 0.3 ng/ml, or three consecutive increases would result in a "false" failure rate of only 3% (3 of 99) and identify 56% (54 of 96) of the true failures after only two PSA increases. CONCLUSION The CPMC definition of two PSA increases can falsely identify patients as failures, particularly if the increases in PSA are small (i.e., < or = 0.3 ng/ml). The CC definition requiring three increases in PSA can falsely identify patients as disease-free when the time to failure is long relative to the follow-up time. We propose a that a definition that combines aspects of both definitions (two consecutive increases in PSA over 3 months, with a final value greater than 1.0 ng/ml and each increase being at least 0.3 ng/ml, or three consecutive increases) may be a better definition of biochemical failure.
Collapse
Affiliation(s)
- R D Ennis
- Department of Radiation Oncology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
| | | | | | | | | | | |
Collapse
|
12
|
Reni M, Bolognesi A. Prognostic value of prostate specific antigen before, during and after radiotherapy. Cancer Treat Rev 1998; 24:91-9. [PMID: 9728419 DOI: 10.1016/s0305-7372(98)90075-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- M Reni
- Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
| | | |
Collapse
|
13
|
Kuban DA, El-Mahdi AM, Schellhammer PF. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it? Semin Radiat Oncol 1998; 8:72-80. [PMID: 9516587 DOI: 10.1016/s1053-4296(98)80002-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Pretreatment prostate-specific antigen (PSA) has been shown to be a powerful predictor of expected outcome after radiation for prostate cancer. Additional measures such as recursive partitioning analysis and PSA Cancer Volume calculations are further refining this useful tool to provide the greatest degree of prognostic information. The post-treatment PSA level is also being used as a means to assess therapeutic efficacy rapidly and objectively. Although no single PSA value has been shown to equate to long-term clinical tumor control consistently, consensus has been reached regarding the value of a rising PSA level as an early surrogate for tumor recurrence. Since the first introduction of PSA as a tumor marker, we have become much more comfortable with what it means, the ways it can help us, and how to use it.
Collapse
Affiliation(s)
- D A Kuban
- Department of Radiation Oncology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
| | | | | |
Collapse
|
14
|
McLean M, Panzarella T, Warde PR, Gospodarowicz M, Duncan W, Catton C, Bissett R. Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate. Clin Oncol (R Coll Radiol) 1997; 9:226-33. [PMID: 9315396 DOI: 10.1016/s0936-6555(97)80006-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
There has been substantial interest in the effect of radiation therapy upon serum prostate specific antigen (PSA) levels in patients managed by radiation therapy and their ability to predict the eventual outcome. At our institute, an observational prospective longitudinal study was begun in 1989 to identify prognostic factors for biochemical relapse from among several variables, including PSA levels measured prior to treatment, during treatment, and post-treatment, and to summarize what happens to PSA levels over the course of treatment with radical radiation therapy. A total of 142 patients with adenocarcinoma of the prostate (T1-4, N0, M0) were radically irradiated (6-7 weeks) between February 1989 and January 1991. Serum PSA levels were recorded weekly during radiation therapy in 117 patients. Of these 117, weekly PSA measurements ranged in completeness from 95 to 113 cases. A number of statistical tests were performed on the data with investigative/ exploratory intent. There were 60 biochemical relapses documented in the whole group of 142 patients, with a maximum follow-up of 4.6 years and median follow-up of 3.3 years. Of the candidate prognostic variables tested by univariate analysis, the following emerged as statistically significant (i.e. P < 0.05): each of the four pretreatment factors (absolute PSA value, dichotomous PSA (normal versus above normal), T category and Gleason score); the treatment variables namely, the end-of-treatment PSA, the slope of PSA, and the absolute change in PSA from pretreatment to the end of treatment; and, among post-treatment variables, the first follow-up PSA, the absolute change in PSA from pretreatment to first follow-up, and the return to normal of an above-normal pretreatment PSA by first follow-up. The majority of these factors were then subjected to multivariate Cox proportional hazards (PH) regression analyses. The end-of-treatment PSA and T category were consistently identified as independently statistically significant factors associated with biochemical relapse. The Gleason score was selected less consistently, and never when defined on a categorical scale. Therefore, using a Cox PH model with the variables of end-of-treatment PSA and T category, both defined on a categorical scale, we developed three prognostic groups with good, intermediate and poor prognoses (chi 2 TREND = 40.7; P < 0.0001). Their 3-year biochemical relapse-free rates, for example, were: 91%, (standard error (SE) 5%); 64% (SE 9%); and 24% (SE 6%), respectively. However, substitution of the baseline value of PSA, which was also strongly associated with outcome, and using the data from all 142 patients, provided similarly distinct prognostic groups (chi 2 TREND = 41.6; P < 0.0001), with corresponding 3-year relapse-free rates of: 92% (SE 4%); 79% (SE 7%); and 30% (SE 6%). Mean weekly PSA levels measured during treatment were found to have a negatively sloping or decreasing tendency. A statistically significant decrease in PSA occurred from pretreatment to the end of treatment (t116 = 7.5; P < 0.0001); the geometric mean of the ratio of end-of-treatment PSA to PSA at pretreatment was 0.7 (95% CI 0.6-0.8). The end-of-treatment PSA and T category emerged as independently statistically significant prognostic variables predicting biochemical relapse. Using the fitted Cox PH model with these two variables, three distinct prognostic groups were identified. The results using pretreatment PSA instead of end-of-treatment PSA produced similarly distinct prognostic groups. Mean weekly PSA levels measured during treatment exhibited a decreasing tendency, and a statistically significant decrease in PSa from pretreatment to the end of treatment was observed.
Collapse
Affiliation(s)
- M McLean
- Princess Margaret Hospital/University of Toronto, Ontario, Canada
| | | | | | | | | | | | | |
Collapse
|
15
|
Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997; 44:213-21. [PMID: 9380819 DOI: 10.1016/s0167-8140(97)00123-0] [Citation(s) in RCA: 143] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND AND PURPOSE To determine the kinetics of serum prostate-specific antigen (PSA) after radiation therapy of localized prostate cancer and to evaluate whether such kinetics provide prognostic information. MATERIALS AND METHODS Eight hundred forty-one men with serial PSA determinations who underwent external beam radiation without androgen ablation were analyzed to determine postradiation PSA kinetic parameters (half-life and doubling time) and to correlate these parameters with disease outcome. Non-linear regression techniques were used to determine half-lives and doubling times. RESULTS The postradiation serum PSA data fitted well to first order kinetic models. The median PSA half-life was 1.6 months (range 0.5-9.2 months). There was no correlation between half-life and T-stage or Gleason grade. A significant but quantitatively weak correlation was present between the pretreatment PSA level and half-life; lower pretreatment levels were associated with longer half-lives. Half-life did not correlate with disease outcome whether the endpoint was local recurrence, distant metastasis or rising PSA. In 263 men with a rising postradiation PSA profile the median PSA doubling time was 12.2 months (range 0.8-80.2 months). Faster doubling times were significantly associated with higher T-stage, higher Gleason grade and higher pretreatment PSA levels. Thus, patients with initially adverse disease developed faster rising PSA values after treatment than patients with less adverse disease. The most striking correlation was between rapid doubling time and the likelihood of metastatic relapse. Patients who developed metastases had a median PSA doubling time of 4.2 months compared to a median doubling time of 11.7 months in patients who developed local recurrence. Overall, patients with a PSA doubling time of less than 8 months had a 7-year actuarial metastatic rate of 54%, while patients with a PSA doubling time exceeding 8 months had only a 7% metastatic rate. Particularly ominous was the combination of a doubling time shorter than 8 months which began to rise within the first year; by 3 years 50% of these men had metastases and all were actuarially projected to develop such relapse by 6.5 years. CONCLUSIONS Overall, the clinical utility of postradiation serum PSA kinetics was small. There were no discernible uses for PSA half-life. In patients with a rising PSA profile the faster the kinetics the more adverse the disease. Doubling times shorter than 8 months, especially if the rise begins in the first year, predict for metastatic relapse. However, in the absence of decisively useful treatment for metastatic prostate cancer the virtues of the early detection of metastases remain unclear.
Collapse
Affiliation(s)
- G K Zagars
- Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
| | | |
Collapse
|
16
|
Martinez A, Gonzalez J, Stromberg J, Edmundson G, Plunkett M, Gustafson G, Brown D, Yan D, Vicini F, Brabbins D. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 1995; 33:1019-27. [PMID: 7493828 DOI: 10.1016/0360-3016(95)00254-5] [Citation(s) in RCA: 82] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
PURPOSE To improve treatment results on prostatic adenocarcinoma, conformal radiation therapy (CRT) has been used. Two major drawbacks of external CRT are: (a) internal organ motion/daily set-up variations, and (b) exclusion of several patients for CRT based on poor geometrical relationships as identified by three dimensional (3D) treatment planning. To overcome the above problems, we began the first prospective Phase I/II dose-escalating clinical trial of conformal brachytherapy (CB) and concurrent external beam irradiation. METHODS AND MATERIALS Fifty-nine patients with T2b-T3c prostatic adenocarcinoma received 176 transperineal ultrasound-guided conformal high-dose rate (HDR) boost implants. All patients received concomitant external beam pelvic irradiation. Dose escalation of the three HDR-CB fractions proceeded as follows: 5.5 Gy (30 patients), 6 Gy (20 patients), and 6.5 Gy (9 patients). The CB dose was prescribed to the prostate contour as outlined using an online biplanar transrectal ultrasound probe. The urethra, anterior rectal wall, and prostate boundaries were identified individually and outlined at 5 mm intervals from the base to the apex of the gland. The CB using real-time ultrasound guidance with interactive online isodose distributions was performed on an outpatient basis. As needles were placed into the prostate, corrections for prostate displacement were recorded and the isodose distributions were recalculated to represent the new relationship between the needles, prostate, and normal structures. No computerized tomography (CT) planning or implant preplanning was required. RESULTS No patient was rejected based on poor geometrical relation of pelvic structures. In every implant performed, prostate displacement was noted. Craniocaudal motion of the gland ranged from 0.5-2.0 cm (mean = 1.0 cm), whereas lateral displacement was 0.1-0.4 cm. With the interactive online planning system, organ motion was immediately detected, accounted for, and corrected prior to each HDR treatment. The rectal dose has ranged from 45 to 87%, and the urethral dose from 97 to 112% of the prostate dose. It is significant to note that operator dependence has been completely removed because the interactive online planning system uniformly guides the physicians. CONCLUSIONS With ultrasound guidance and the interactive online dosimetry system, organ motion (as compared to external beam) is insignificant because it can be corrected during the procedure without increasing target volume margins. Common pitfalls of brachytherapy, including operator dependence and difficulty with reproducibility, have been eliminated with the intraoperative online planning system.
Collapse
Affiliation(s)
- A Martinez
- Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48073, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Stromberg J, Martinez A, Gonzalez J, Edmundson G, Ohanian N, Vicini F, Hollander J, Gustafson G, Spencer W, Yan DI. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 1995; 33:161-71. [PMID: 7543891 DOI: 10.1016/0360-3016(95)00035-w] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
PURPOSE To improve results for locally advanced prostate cancer, a prospective clinical trial of concurrent external beam irradiation and fractionated iridium-192 (Ir-192) high dose rate (HDR) conformal boost brachytherapy was initiated. METHODS AND MATERIALS Between November 1991 and February 1994, 99 implants were performed on 33 patients with prostatic adenocarcinoma at William Beaumont Hospital. Using AJCC staging criteria, 9 patients had T2b tumors, 17 patients had T2c tumors, and 7 patients had T3 disease. Patients were treated with (a) 45.6 Gy whole pelvis external irradiation and (b) three HDR fractions of 5.5 Gy each (18 patients) or 6 Gy each (15 patients) to the prostate. Transperineal needle implants using real-time ultrasound guidance with interactive on-line isodose distributions were performed on an outpatient basis during weeks 1, 2, and 3 of external irradiation. Acute toxicity was scored using the Radiation Therapy Oncology Group (RTOG) morbidity grading system. RESULTS This technique of concurrent external pelvic irradiation and conformal HDR brachytherapy was well tolerated. No significant intraoperative or perioperative complications occurred. Three patients (9%) experienced Grade 3 acute toxicity (two dysuria and one diarrhea). All toxicities were otherwise Grades 1 or 2 and were primarily as expected from pelvic external irradiation. Persistent implant-related toxicities included Grades 1-2 perineal pain (12%) and hematospermia (15%). Median follow-up time was 13 months. Serum prostatic-specific antigen (PSA) levels normalized in 91% of patients (29 out of 32) within 1-14 months (median 2.8 months) after irradiation. PSA levels were progressively decreasing in the other three patients at last measurement. Prospectively planned prostatic rebiopsies done at 18 months in the first 10 patients were negative in 9 out of 10 (90%). CONCLUSIONS Acute toxicity has been acceptable with this unique approach using conformal high dose rate Ir-192 boost brachytherapy with concurrent external irradiation. The initial tumor response as assessed by serial PSA measurement and rebiopsy is extremely encouraging. Dose escalation will proceed in accordance with the protocol guidelines. Further patient accrual and longer follow-up will allow comparison to other techniques.
Collapse
Affiliation(s)
- J Stromberg
- Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48073, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Corn BW, Hanks GE, Schultheiss TE, Hunt MA, Lee WR, Coia LR. Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys 1995; 32:325-30. [PMID: 7503847 DOI: 10.1016/0360-3016(94)00618-u] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
PURPOSE Conformal radiation therapy (CRT) decreases the morbidity of prostate cancer treatment, but no published data attest to the improved ability of CRT to control disease. Therefore, we compared Prostate-Specific Antigen (PSA) response at 1 year among similarly staged patients treated by conformal techniques to those treated with conventional approaches, looking for an early indicator of tumor response. METHOD AND MATERIALS Patients with locally advanced disease were treated by pelvic field followed by prostate field conedowns; those with early stage/low grade disease received only prostate field irradiation. Between October, 1987 and November, 1991, conventional treatments used rectangular beams with or without corner blocks. Neither urethrography nor immobilization casts were used for conventionally treated patients. Between April, 1989 and December, 1992, conformal treatments have used rigid immobilization and Computed Tomography-based, beams-eye-view field design. As such, our conformal approach allowed improved targeting. Median prescribed doses (minimal doses to the Planning Target Volume) were 70 Gy (66-73 Gy) and 70.2 Gy (64.8-75 Gy) for conventionally and conformally treated patients, respectively. Median daily fraction size was 1.8 Gy for conventional treatment and 2.0 Gy for conformal therapy. Baseline PSA data were available on 170 consecutive patients treated conformally and 90 consecutive patients treated conventionally. RESULTS Among those receiving only prostatic field irradiation, 12-month PSA values returned to normal in 96% and 85% of conformally and conventionally treated patients, respectively, when normalization was defined as < or = 4 ng/ml (p < 0.03) and in 76% vs. 55% of patients when PSA normalization was defined as < or = 1.5 ng/ml (p < 0.02). Among those receiving pelvic irradiation prior to prostatic conedown, PSA normalization (< or = 4 ng/ml) occurred in 82% and 61% (p < 0.01) of conformally and conventionally treated patients, respectively, and in 56% vs. 38% of patients when normalization was defined as < or = 1.5 ng/ml (p < 0.05). In a multivariate analysis, pretreatment PSA level (< or = 15 vs. > 15), and the use of conformal irradiation were statistically significant prognostic discriminants of PSA normalization at 1 year while total irradiation dose, clinical stage, and the addition of pelvic fields were not significant. CONCLUSIONS As measured by PSA normalization, conformal techniques with improved targeting produced responses that were significantly better than conventional techniques among patients treated with definitive irradiation. These results, coupled with our previously documented reduction of acute and chronic sequelae, support the continued use of CRT as a more effective method of treatment for prostate cancer.
Collapse
Affiliation(s)
- B W Corn
- Conjoint Department of Radiation Oncology, Fox Chase Cancer Center, Medical College of Pennsylvania, USA
| | | | | | | | | | | |
Collapse
|
19
|
Ennis RD, Fischer DB, Pcschel RE. Early prostate specific antigen (PSA) response predicts PSA nadir in patients with prostate cancer treated with external beam radiation. ACTA ACUST UNITED AC 1995. [DOI: 10.1002/roi.2970030406] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
20
|
Joensuu TK, Blomqvist CP, Kajanti MJ. Primary radiation therapy in the treatment of localized prostatic cancer. Acta Oncol 1995; 34:183-91. [PMID: 7536428 DOI: 10.3109/02841869509093954] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Prostatic carcinoma is one of the leading causes of male cancer deaths. However, the routine diagnostic and therapeutic strategies have not yet been established. Although the outcome of surgical and radiotherapeutical approaches has frequently been reported to be comparable, the profile of side effects is different. This could offer the basis for selecting the treatment of choice in individual cases. During the last decade the radiotherapeutical technique has markedly improved, in part due to the achievements in the field of computer assisted tomography planning and conformal technique; the outcome of side-effects has decreased with concurrent increase in the rate of local control. The prescribing, recording and reporting of irradiation have also recently developed, as well as the staging of the disease. Therefore we consider it timely to review progress in this subject and to emphasize the role of radiotherapy in the treatment of localized prostatic cancer.
Collapse
Affiliation(s)
- T K Joensuu
- Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland
| | | | | |
Collapse
|
21
|
Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Kelson S, Fuks Z. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J Urol 1994; 152:1792-8. [PMID: 7933238 DOI: 10.1016/s0022-5347(17)32387-x] [Citation(s) in RCA: 83] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Acute morbidity, late complications and tumor response were evaluated in 324 prostate cancer patients treated with 3-dimensional conformal radiation therapy in a phase I dose-escalation study. This radiotherapy technique targeted the prostate and seminal vesicles but effectively excluded the surrounding normal tissues. The minimum tumor dose was 64.8 to 66.6 Gy. in 87 patients, 70.2 Gy. in 138, 75.6 Gy. in 69 and 81.0 Gy. in 30. The treatment was well tolerated with minimal acute morbidity, observed in 15% of the patients who required medication for relief of rectal symptoms and in 34% for urinary symptoms. Two patients (0.6%) to date have had grades 3 and 4 late complications (Radiation Therapy Oncology Group morbidity grading system). The 3-year actuarial probability of survival with a normal serum prostate specific antigen level was 97% for patients with stages T1c and T2a, 86% with stage T2b, 60% with stage T2c and 43% with stage T3 disease. A multivariate analysis demonstrated that initial prostate specific antigen (20 ng./ml. or less versus more than 20 ng./ml.), stage (T2c or less versus T3) and Gleason score (6 or less versus 7 or more) were each significant independent variables that affected subsequent chemical relapse. The acute and long-term toxicities have been less compared with traditional treatment techniques. After the maximal tolerable dose with 3-dimensional conformal radiotherapy is established, future studies will test whether high dose conformal therapy has the potential to improve local tumor control and survival of patients with localized prostatic carcinoma.
Collapse
Affiliation(s)
- S A Leibel
- Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
| | | | | | | | | | | |
Collapse
|
22
|
Kavadi VS, Zagars GK, Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 1994; 30:279-87. [PMID: 7523340 DOI: 10.1016/0360-3016(94)90005-1] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
PURPOSE Serum prostate-specific antigen (PSA) levels following definitive radiation for prostate cancer are increasingly recognized as the most sensitive means to monitor disease status. However, beyond general agreement that patients fare poorly when posttreatment PSA levels fail to normalize, many questions relative to postirradiation PSA remain unanswered. This study evaluates the potential prognostic value of postirradiation PSA in a large cohort of patients followed with serial PSA determinations. METHODS AND MATERIALS We analyzed disease outcome in 427 patients with clinical stages T1 (122 men), T2 (147 men), T3 (152 men), and T4 (six men) prostate cancer receiving definitive external radiation as sole therapy and followed for times ranging from 9-73 months (median 30 months) with a total of 2260 posttreatment PSA values. RESULTS Excluding three patients who died due to intercurrent illness without a posttreatment PSA, postirradiation PSA fell in 416 of 424 men (98%). Prostate-specific antigen levels continued to fall for up to 12 months but there was no evidence of significant declines beyond that. The time to nadir PSA was: 3 months, 60 patients; 6 months, 68 patients, 9 months 148 patients; 12 months, 144 patients. Time to nadir was not a significant determinant of outcome. Prostate-specific antigen levels at 3 and 6 months and the nadir level were individually highly correlated with outcome. In multivariate analyses of posttreatment values, only the nadir value was independently significant, with increasing relapse rates as its value was higher. It retained significance when pretreatment PSA level was included in the model. Nadir values ranged from undetectable (52 patients) to 20.3 ng/ml with a median of 1.1 ng/ml. Nadir values down to 1 ng/ml were prognostic; below 1 ng/ml (182 patients) the nadir value no longer yielded prognostic information additional to that inherent in the pretreatment value. Only patients with nadir levels < 1 ng/ml fared well (5-year incidence of relapse or rising PSA 17%); however, if the pretreatment level exceeded 30 ng/ml, then even a nadir level < 1 ng/ml was associated with a 40% failure rate at 5 years. CONCLUSION The nadir PSA value after radiation is a significant posttreatment determinant of outcome and was second only to the pretreatment value. Surprisingly low nadir values were prognostically significant. Only patients whose nadir falls below 1 ng/ml can be said to have achieved a biochemical complete remission. However, even such low nadir values do not portend durable disease control for patients with high pretreatment PSA levels.
Collapse
Affiliation(s)
- V S Kavadi
- Department of Clinical Radiotherapy, University of Texas, M.D. Anderson Cancer Center, Houston 77030
| | | | | |
Collapse
|
23
|
Abstract
OBJECTIVE To determine if prostate-specific antigen (PSA) is the most effective analyte for diagnosing, staging, and monitoring prostatic carcinoma. METHODS This article reviews what PSA is and how it can be used to detect clinically significant carcinomas as well as its application in managing patients after radical prostatectomy, radiation therapy, and androgen deprivation therapy. RESULTS PSA screening results in increased detection of localized disease. In individual patients a serum PSA level is not a good indicator of pathologic stage; however, a serum PSA level of greater than 10 ng/mL is associated with a higher incidence of extracapsular disease. Asymptomatic patients with newly diagnosed untreated prostate cancer and a serum PSA level less than 10 ng/mL do not need to undergo staging radionuclide bone scan. Elevated serum PSA is generally the first indicator of "persistent disease" after radical prostatectomy and radiation therapy. In androgen deprivation the PSA nadir is an important indicator of response to therapy. CONCLUSIONS PSA is the most accurate tumor marker in oncology. This analyte can be successfully used to diagnose, stage, and monitor prostatic carcinoma.
Collapse
Affiliation(s)
- N R Ploch
- Department of Urology, University of Washington School of Medicine, Seattle
| | | |
Collapse
|
24
|
Leibel SA, Heimann R, Kutcher GJ, Zelefsky MJ, Burman CM, Melian E, Orazem JP, Mohan R, LoSasso TJ, Lo YC. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study. Int J Radiat Oncol Biol Phys 1994; 28:55-65. [PMID: 7505776 DOI: 10.1016/0360-3016(94)90141-4] [Citation(s) in RCA: 137] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
PURPOSE The acute morbidity of doses of 64.8-75.6 Gy and preliminary observations of late complications and tumor response using 3-dimensional conformal radiation therapy in carcinoma of the prostate are assessed. METHODS AND MATERIALS 123 patients (Stage A2-12, B1-17, B2-43, C-51) were irradiated to the prostate and seminal vesicles using a 3-dimensional conformal radiation therapy technique. The median follow-up time was 15.2 months. The minimum tumor dose was 64.8-66.6 Gy in 49 patients, 70.2 Gy in 46, and 75.6 Gy in 28. Toxicity was scored according to the Radiation Therapy Oncology Group morbidity grading system. RESULTS This technique of 3-dimensional conformal radiation therapy was well-tolerated with minimal acute morbidity. Only 32% of patients had grade 2 or 3 acute morbidity requiring short-term medication for relief of urinary symptoms or diarrhea. Only one patient (0.8%) has so far developed a severe (grade 4) late complication. Serum prostate specific antigen concentrations normalized in 67% of patients (64/96) within 1-14 months (median 4.5 months) after treatment and were progressively decreasing at last measurement in an additional 22% (21/96). Abnormal rising prostate specific antigen levels were observed in 15 patients, 11 of whom have already developed other evidence of relapsing disease. CONCLUSION Acute toxicity for the doses tested with this 3-dimensional conformal radiation therapy technique is reduced compared to traditional treatment techniques, and the initial tumor response as assessed by prostate specific antigen measurement is highly encouraging with prostate specific antigen levels returning to normal in the majority of patients. Based on these results, a further increase of the dose to 81 Gy has been implemented in accordance with the schema of an ongoing Phase I dose-escalation study.
Collapse
Affiliation(s)
- S A Leibel
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Perez CA, Hanks GE, Leibel SA, Zietman AL, Fuks Z, Lee WR. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. Cancer 1993; 72:3156-73. [PMID: 7694785 DOI: 10.1002/1097-0142(19931201)72:11<3156::aid-cncr2820721106>3.0.co;2-g] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND Optimal treatment for patients with localized carcinoma of the prostate is controversial. Radiation therapy is an established modality in the management of these patients, and several reports indicate the results are comparable to those achieved with radical prostatectomy. Recently effectiveness of therapy for carcinoma of the prostate is being evaluated in light of post-treatment prostate-specific antigen (PSA) determinations. METHODS A review was performed of multiple publications and data from selected institutions with large experience in the management of carcinoma of the prostate. Survival and clinical incidence of local recurrence and distant metastases were analyzed as well as preliminary data on postirradiation PSA levels. Factors that affect the outcome of therapy and relevant clinical trials are discussed. RESULTS Reported differences in the age of patients treated with radical prostatectomy (59-63 years), irradiation (63-69 years), or observation (69-75.5 years) were identified. The effect of surgical staging on outcome of irradiation was significant. In multiple series of patients clinically and radiographically staged, the 5-year disease-free survival (DFS) with external irradiation was 95-100% for clinical stage T1a, 80-90% for Stage T1b,c, and 50-70% for clinical Stage T3. A correlation has been identified between the initial PSA levels and the probability from freedom of chemical failure (PSA elevation) after definitive irradiation. In five series comprising 814 patients with Stage T1c and T2 tumors, the DFS (end point chemical failure) was 95%, with initial PSA of less than 4 ng/ml, 83-92% with 4.1-10 ng/ml, 35-85% with 10.1-20 ng/ml, and 10-63% with PSA higher than 20 ng/ml. In the various series, follow-up ranged from a median of 1.5 years to a minimum of 4 years. In two series of 225 and 201 patients receiving doses of 7500-8000 cGy, less morbidity has been observed with three-dimensional treatment planning conformal radiation therapy than with conventional irradiation. New directions for future clinical trials are discussed, including dose escalation studies; use of high linear energy transfer to improve locoregional tumor control; and combination of irradiation and androgen suppression to enhance local tumor control, decrease distant metastasis, and improve survival. Preliminary results of a randomized study recently reported by RTOG strongly suggest that the use of goserelin acetate and flutamide decreases the incidence of clinical local recurrence (12.4% in 225 patients) compared with a control group treated with irradiation alone (25.2% in 230 patients) and enhances disease-free survival. CONCLUSIONS Although modern approaches to the management of patients with localized carcinoma of the prostate with irradiation are effective, investigators must continue to critically assess policies of treatment, develop appropriately designed prospective clinical trials, and define the optimal management of patients with localized carcinoma of the prostate.
Collapse
Affiliation(s)
- C A Perez
- Radiation Oncology Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | | | | | | | | | | |
Collapse
|
26
|
|
27
|
Zentner PG, Pao LK, Benson MC, McMahon DJ, Schiff PB. Prostate-specific antigen density: a new prognostic indicator for prostate cancer. Int J Radiat Oncol Biol Phys 1993; 27:47-58. [PMID: 7690018 DOI: 10.1016/0360-3016(93)90420-z] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
PURPOSE Prostate specific antigen density, previously described as a ratio of serum prostate specific antigen to the volume of the prostate, has been shown to be an important factor in the discrimination of patients with occult metastatic disease and patients with benign versus malignant prostatic disease. We undertook a retrospective study to determine if prostate specific antigen density was a predictor of outcome following definitive conformal radiation therapy. METHODS AND MATERIALS Between January 1989 and August 1991, 86 patients with localized prostate cancer (confined to the prostate, periprostatic tissue, or seminal vesicles) were treated in the Department of Radiation Oncology, Columbia-Presbyterian Medical Center with definitive radiation therapy using computed tomography-guided conformal technique. Thirteen patients were excluded on the basis of prior prostatectomy, hormonal therapy, or no pretreatment prostate specific antigen measurement. Seventy-three patients were evaluable: 19% (14/73) American Urologic Association Stage A (T1), 41% (30/73) B (T2), and 40% (29/73) C (T3). Prostate specific antigen density was defined as the ratio of the pretreatment serum prostate specific antigen to the prostate volume as determined from computed tomography treatment planning scans. Pretreatment prostate specific antigen density was calculated for each patient and ranged from 0.04-3.85 with a mean and median value of 0.66 and 0.33, respectively. Prostate specific antigen failure was defined as a rise above normal level or, for patients whose nadir was above 4 ng/ml, an increase of greater than 10% above nadir. Mean prostate specific antigen follow-up was 13 months (range 2.3-31 months) by which time 66% of patients had normal prostate specific antigen (< or = 4 ng/ml) levels. RESULTS Nine patients experienced prostate specific antigen failure. The mean prostate specific antigen density of patients with disease-free survival versus failures was 0.53 and 1.6, respectively (p < 0.05). Kaplan-Meier analysis showed that patients with a prostate specific antigen density < or = 0.3 (n = 30) had 100% actuarial disease-free survival at 30 months compared with 62% for patients with prostate specific antigen density > 0.3 (n = 43, p < 0.01). Patients with a prostate specific antigen density < or = 0.6 (n = 52) and > 0.6 (n = 21) had an 88% and 57% actuarial disease-free survival at > 24 months (p < 0.05). CONCLUSION Prostate specific antigen density was an excellent predictor of disease-free survival (p < 0.01) and was superior to clinical stage (p > 0.05), Gleason's score (p > 0.05), and pretreatment prostate specific antigen (p < 0.05). These results suggest that patients with low prostate specific antigen density (< or = 0.3), including those with locally advanced clinical stage, high Gleason's score, or elevated pretreatment prostate specific antigen, do well with conventional radiation therapy and should not be subjected to high risk protocols. Further follow-up will be required to determine if patients with low prostate specific antigen density will have improved overall survival.
Collapse
Affiliation(s)
- P G Zentner
- Department of Radiation Oncology, College of Physicians and Surgeons of Columbia University, New York, NY 10032
| | | | | | | | | |
Collapse
|
28
|
Zagars GK, Pollack A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 1993; 72:832-42. [PMID: 7687516 DOI: 10.1002/1097-0142(19930801)72:3<832::aid-cncr2820720332>3.0.co;2-6] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND The serum kinetics of prostate-specific antigen (PSA) after radiation therapy for prostate cancer are not well characterized, and the potential prognostic significance of serum half-lives and of serum doubling times is unclear. This study was designed to address those issues. METHODS One hundred fifty-four patients with at least four serial PSA determinations who received external-beam radiation therapy alone were analyzed to determine PSA kinetics and to correlate kinetic parameters with outcome. Nonlinear regression techniques were used to estimate PSA half-lives and doubling times. RESULTS The PSA data fitted well to exponential models consistent with the hypothesis that PSA kinetics after radiation follow first-order (exponential) kinetics. The mean PSA half-life was 1.9 months (range, 0.5 to 9.2 months). No significant correlation existed between half-life and grade, stage, acid phosphatase level, serum testosterone level, or patient age. A weak correlation between half-life and pretreatment PSA level was observed: patients with low PSA levels tended to have longer half-lives. Half-life did not correlate with disease relapse or with the likelihood of developing a rising PSA profile. PSA doubling time in 37 patients with rising values ranged from 1.6 to 53 months (mean, 12.5 months). Doubling times were significantly longer than half-lives by an average factor of 6.5 and there was no correlation between half-life and subsequent doubling time. Doubling times were longer in low-grade tumors. CONCLUSIONS Serum kinetics of PSA in particular its rate of fall after radiation provide little, if any, useful clinical information. It is possible that serum kinetics of PSA are related to tumor cell kinetics but such relationships remain speculative. Correlative cell kinetic--PSA kinetic studies are needed to elucidate the mechanisms underlying the changes in PSA level after radiation therapy.
Collapse
Affiliation(s)
- G K Zagars
- Department of Radiotherapy, University of Texas, M.D. Anderson Cancer Center, Houston 77030
| | | |
Collapse
|
29
|
Schellhammer PF, el-Mahdi AM, Wright GL, Kolm P, Ragle R. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology 1993; 42:13-20. [PMID: 7687077 DOI: 10.1016/0090-4295(93)90325-5] [Citation(s) in RCA: 90] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Prostate-specific antigen (PSA) levels after radiation therapy will more precisely and objectively identify the presence of persistent prostate carcinoma. We determined the impact of PSA marker levels on progression-free status for 123 patients treated by interstitial implantation (I-125) and 311 patients treated by external beam therapy (XRT) who have been followed for a median of 109 and 51 months, respectively. Actuarial progression-free survival curves were calculated, using standard clinical criteria, and then recalculated, using PSA marker criteria. Sera obtained twelve months or more after the initiation of XRT and twenty-four months or more after the date of I-125 were used for determination of PSA levels. Using normal PSA level (by Hybritech assay < or = 4.0 ng/mL) as the criterion for progression-free status for patients treated by XRT, 35 percent of patients with Stage A2, 20 percent of patients with Stage B1 or B2, and 10 percent of patients with Stage C tumor were progression-free at ten years. The progression-free survival by clinical criteria for Stage A2 and 65 percent, B1 was 40 percent, B2 was 35 percent, and C was 25 percent. Using undetectable PSA level (< or = 0.5 ng/mL) as the criterion, less than 10 percent of patients were progression-free at ten years, regardless of stage, grade; and treatment modality. This information should not be interpreted as indicating that radiation is ineffective therapy for prostate cancer, since clinical control of the disease among men in their eighth decade is a more practical goal than marker control. However, PSA monitoring after radiation therapy and after any local therapy for prostate cancer will provide more precise information on the success of that therapy in ablating disease.
Collapse
|
30
|
Current status of prostate-specific antigen in the radiotherapeutic management of prostatic cancer. Semin Radiat Oncol 1993. [DOI: 10.1016/s1053-4296(05)80112-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
31
|
Saroja KR, Oesterling JE, Hendrickson F, Cohen L, Mansell J. Prognostic implications of prostate-specific antigen in patients with locally advanced prostate cancer treated with high energy neutron beam therapy: preliminary results. Urology 1993; 41:540-7. [PMID: 7685957 DOI: 10.1016/0090-4295(93)90101-f] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Serial serum prostate-specific antigen (PSA) levels were analyzed retrospectively for prognostic implications in 70 patients with locoregional (Stages B2, C, and D1) prostate cancer who were managed with high energy neutron beam therapy. Three groups of patients were identified. Group I included 30 patients whose serum PSA level decreased to the reference range (0-4 ng/mL) following neutron therapy and remained so subsequently: 28 (93%) remained disease-free and 2 (7%) have failed distantly. All 30 patients (100%) had no evidence of locally progressive disease. This group was categorized as having a good prognosis. The mean time for serum PSA value to decline to reference range was six months; calculated mean time to achieve a stable base-line PSA was 53 +/- 37 days. Follow-up period ranged from twelve to fifty-six months (median: 21 months). Group II consisted of 13 patients in whom there was an initial decrease in serum PSA to reference range followed by a subsequent increase: 6 of 13 (46%) have no overt clinical progression of disease; 7 (54%) have either persistent locoregional or distant metastatic disease. Follow-up period was from twelve to seventy-two months (median: 39 months). Calculated mean time to achieve stable baseline PSA for serum PSA in this group was 61 +/- 21 days. Group III patients had a persistently elevated or rising serum PSA concentration. Of 27 patients in this group, only 9 (33%) have no evidence of disease progression, while 18 patients (67%) have failed already, either locoregionally or distantly. Follow-up period ranged from twelve to sixty-nine months (median: 21 months). Mean time to achieve stable baseline of serum PSA in this cohort of patients with a poor prognosis was 108 +/- 76 days. We conclude that PSA has a predictable prognostic value in patients with locally advanced prostate cancer managed with high energy neutron beam therapy. Rapid normalization of PSA after therapy indicates a good prognosis. Persistent elevation signifies either presence of persistent locoregional disease or development of distant metastases. Subsequent elevation of the serum PSA concentration after definitive therapy signals progression of prostate cancer.
Collapse
Affiliation(s)
- K R Saroja
- Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois
| | | | | | | | | |
Collapse
|
32
|
Wallner K, Roy J, Zelefsky M, Harrington P, Fuks Z, Harrison L. Short-term results of computerized tomographic-based transperineal iodine-125 prostate implantation. ACTA ACUST UNITED AC 1993. [DOI: 10.1002/roi.2970010308] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
33
|
Fijuth J, Chauvet B, Vincent P, Félix-Faure C, Reboul F. Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy. Radiother Oncol 1992; 23:236-40. [PMID: 1376935 DOI: 10.1016/s0167-8140(92)80127-5] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
In order to assess the value of serum prostate-specific antigen (PSA) levels in the monitoring of patients with localized prostatic carcinoma undergoing radical radiation therapy, 146 previously untreated patients were entered into this study. Sixty to 70 Gy were administered to the prostate over 8 to 9 weeks. Serum PSA levels were measured prior to radiotherapy, every 3 months during the first year and every 6 months thereafter. Median follow-up was 28 months. Pretreatment PSA values exceeded 10 ng/ml in 62% (91/146). Initial PSA values were correlated with tumor size and Gleason score. Six months after completion of radiation therapy, PSA levels decreased as compared to initial value in 88.3% of the patients. It had fallen to 10 ng/ml or less in 54 (59%) out of the 91 patients with initial abnormal PSA levels. Patients whose initial PSA exceeded 50 ng/ml attained levels of 10 ng/ml or less in only 19% of the cases (6/32). Only 3 of the 55 patients (5.5%) with both initial and 6-month PSA values less than or equal to 10 ng/ml developed metastasis. Out of the 91 patients with initial PSA values over 10 ng/ml, 54 (59.6%) had a 6-month PSA level of 10 ng/ml or less, and only 4/54 (7.4%) relapsed. By contrast, 13 of the 37 patients (35.1%) with a 6-month PSA value persistently above 10 ng/ml relapsed. The 3-year relapse-free survival is 85.1% for patients with a 6-month PSA level less than or equal to 10 ng/ml, and 50.2% for patients with persistently elevated PSA values.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J Fijuth
- Clinique Sainte Catherine, Avignon, France
| | | | | | | | | |
Collapse
|